{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.00","upperLimit":"67.99","value":"54.94"},{"comment":"NA = The upper limit of the confidence interval is not estimable because of an insufficient number of events at the time of analysis.","groupId":"OG001","lowerLimit":"44.15","upperLimit":"NA","value":"63.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"A stratified Cox regression analysis was used to test for any treatment effect.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"Every 6 months for up to 3 years after first dose","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}